Dabur India, India’s leading FMCG company, has announced 72.15 per cent acquision of Fem Care pharma, a leading player in women skincare products market.
“Acquisition of Fem Care pharma is in line with our strategy to aggressively expand Dabur’s scale of operations and strengthen its presence in FMCG. This transaction will give Dabur an entry to skin care market,” said Dr Anand Burman, chairman, Dabur India.
The strength of Dabur will help expand the distribution of Fem’s brands across India and faster growth for the company, both in India and abroad,” said Sunita Ramnathkar, joint managing director, Fem Care Pharma.
Dabur India entered into the share purchase agreement with the existing promoters of Fem Care Pharma for acquisition of 25,46,596 equity shares of Rs 10 each of FEM representing 72.15 per cent of the fully diluted paid up equity share capital of FEM (including 5,21,300 equity shares which are to be issued pursuant to the scheme of merger with Mirasu Marketing, a subsidiary of FEM) at a price of Rs 800 per equity share.
Interestingly, weeks ago when Indiaretailing asked Dabur India officials about the deal, they termed the reports as speculative only.